Tender detail
Non-exclusive medicine discount agreement for clindamycin and benzoyl peroxide
Summary
DAK-Gesundheit intends to conclude non-exclusive medicine discount agreements with interested pharmaceutical companies for medicines containing clindamycin and benzoyl peroxide (ATC D10AF54). The agreements are scheduled to run from 1 January 2027 to 31 December 2028, with an option to extend once for 12 months. They will end earlier if an exclusive agreement for the active ingredient takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.